ESALF News and Press, Eisai Co Ltd From 07/13/21

drnadig/iStock via Getty Images U.S. lawmakers investigating the controversial FDA approval granted for Alzheimer’s therapy Aduhelm (aducanumab) have asked Biogen (BIIB) to submit years of internal documents related to the drug’s development and the company’s interactions...

travellinglight/iStock via Getty Images Biogen (BIIB) and Eisai (ESALF) announce that the FDA has approved an updated label for Aduhelm (aducanumab-avwa) injection 100 mg/mL solution. The update includes an addition to the Indications and Usage section of the label to emphasize the disease st...

Eisai shares climb (ESALF) more than 10% on the back of announcing that its Hong Kong subsidiary launched its orexin receptor antagonist DAYVIGO (lemborexant) for the treatment of adults with insomnia.Eisai received approval for DAYVIGO in Hong Kong in February, and this launch...

Galapagos has over $6.2 billion in cash with no debt and a market capitalization of only $4.5 billion. The company has an approved product that is expected to generate €500 million annually in sales in Europe in the medium term. The partnership with biotech giant Gilead dem...

Biogen (BIIB) and Eisai (ESALF), (ESALY) announced that the FDA granted Breakthrough Therapy designation for lecanemab (BAN2401), an investigational humanized monoclonal antibody for Alzheimer's disease ((AD)).Breakthrough Therapy designation aimed to accelerate the research work and rev...

solarseven/iStock via Getty Images Next year at this time, the markets might be closed for the new Juneteenth federal holiday. For today, though, trading remain open, with Bristol Myers (BMY), CAI International (CAI), Geron (GERN) and Athira Pharma (ATHA) all making news before Friday's open....

metamorworks/iStock via Getty Images Bristol-Myers Squibb (BMY) and Eisai (ESALF) have announced a global collaboration to jointly develop and commercialize MORAb-202, an antibody-drug conjugate ((ADC)) currently undergoing studies in Japan and the U.S. for a range of cancers. The two compani...

selvanegra/iStock via Getty Images A 70-year-old male is expected to become the first patient outside of a clinical trial to receive the recently-approved Alzheimer’s therapy Aduhelm developed by Biogen (BIIB) and Eisai (ESALF). The infusion is set to take place in Providence...

Stocks had quiet start to the week, with investors anxiously awaiting Thursday's consumer price index report. That exceeded expectations, but apparently not by enough to spook markets. Tech stocks in particular rallied and the S&P 500 closed at a record high on Thursday, June 10. At the t...

Photo by selvanegra/iStock via Getty Images Biogen ([[BIIB]] +0.3%) shares have reached the highest level in the year so far as the investors eagerly await the FDA decision on aducanumab, the experimental therapy against Alzheimer’s disease. The FDA set a new action date for June 07 wh...